CS
IRON icon

Credit Suisse’s Disc Medicine IRON Stock Holding History

Credit Suisse’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$647K Buy
10,387
+2,460
+31% +$159K ﹤0.01% 2516
2023
Q4 		$458K Buy
7,927
+1,791
+29% +$91.7K ﹤0.01% 2770
2023
Q3 		$288K Buy
+6,136
New +$307K ﹤0.01% 2949
2022
Q3 		– Hold
0
– – – 4153
2022
Q2 		– Hold
0
– – – 4119

Other funds holding IRON

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Credit Suisse's IRON Position: Q1 2024 in Review

Credit Suisse increased its Disc Medicine (IRON) stake by 31% in Q1 2024, buying an estimated $159K and bringing the position to 10,387 shares worth $647K. The position accounts for ﹤0.01% of the portfolio, ranked #2516.

Credit Suisse first reported a position in IRON in Q3 2023 and has held it in 3 quarters since. 130 funds tracked by Wall St. Rank hold IRON as of Q1 2024.

  • Credit Suisse held 10,387 shares of Disc Medicine worth $647K as of Q1 2024.
  • Credit Suisse bought 2,460 Disc Medicine shares in Q1 2024, an estimated $159K.
  • Disc Medicine made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2516 holding.
  • Credit Suisse first reported a position in Disc Medicine in Q3 2023 and has held it in 3 quarters since.
  • 130 funds tracked by Wall St. Rank held Disc Medicine as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.